Can I Take CoQ10 with BPC-157? A Women's Health Guide to Combining These Two

What the question really means: are BPC-157 and CoQ10 safe together?

The short answer is that no published pharmacokinetic study documents a meaningful interaction between BPC-157 pentadecapeptide and coenzyme Q10. They do not compete for the same cytochrome P450 enzymes, do not share protein-binding sites, and are not eliminated by the same renal or hepatic pathways. The interaction concern worth taking seriously is pharmacodynamic rather than pharmacokinetic: both compounds have been associated with blood-pressure-lowering effects in animal models, and stacking them on top of a prescribed antihypertensive could push your pressure lower than intended.

That framing matters for women specifically. Perimenopausal women are the fastest-growing group starting statins in the United States, and statin use directly depletes CoQ10 by blocking the mevalonate pathway 1. At the same time, interest in BPC-157 for joint recovery, gut repair, and hormonal-transition fatigue is climbing among women in their 40s and 50s. Understanding what you are actually stacking, and where the real risks sit, is the only way to make an informed choice.

What BPC-157 actually is

BPC-157 (Body Protective Compound 157) is a synthetic pentadecapeptide consisting of 15 amino acids. It is derived from a sequence found in human gastric juice and has been studied primarily in rodent models for its effects on tendon healing, gut-barrier repair, and angiogenesis 2. In the United States, it is dispensed as a compounded preparation under FDA 503A pharmacy rules. It is not FDA-approved as a drug, and in March 2022 the FDA placed BPC-157 on its list of bulk substances that may not be used in compounding because it presents "significant safety concerns" and has not been shown to be safe and effective 3.

What CoQ10 actually is

Coenzyme Q10 (ubiquinone or ubiquinol) is a fat-soluble compound made in every cell that functions as an electron carrier in mitochondrial Complex I and Complex III 4. It also acts as a lipid-phase antioxidant. Endogenous production declines from roughly age 30 onward, meaning perimenopausal and postmenopausal women have measurably lower tissue levels than they did at 25 5. CoQ10 is sold over the counter in doses ranging from 30 mg to 600 mg and is widely used for cardiovascular support, fertility, migraine prevention, and statin-associated myopathy relief.

How each compound works in your body

BPC-157 mechanism

BPC-157 does not appear to work through any single receptor. In animal studies it modulates nitric oxide (NO) signaling, upregulates growth hormone receptor expression in tendon fibroblasts, and stabilizes the endothelium 2. The NO-pathway activity is the reason a blood-pressure signal shows up in rodent pharmacology: animals given BPC-157 show vasodilation, and this effect is blocked by L-NAME (a nitric oxide synthase inhibitor), confirming the mechanism is NO-dependent 6.

Oral bioavailability of BPC-157 in rodents appears meaningful despite the peptide being susceptible to gastric proteolysis, which is one of the claims made about its gastric-origin stability. No human pharmacokinetic data has been published in peer-reviewed literature as of mid-2025.

CoQ10 mechanism and the statin connection

CoQ10 is absorbed in the small intestine as part of dietary fat digestion, incorporated into chylomicrons, and delivered to peripheral tissues. Peak plasma concentration occurs 5-10 hours post-dose 7. Statins inhibit HMG-CoA reductase, blocking the mevalonate pathway that produces both cholesterol and ubiquinone. The result is a measurable drop in plasma CoQ10 of roughly 16-54% depending on the statin and dose 1. This is why CoQ10 supplementation is commonly recommended alongside statin therapy, even though the evidence for reducing myopathy symptoms is mixed.

CoQ10 itself has mild antihypertensive properties. A meta-analysis of 12 trials found a mean systolic reduction of 16.6 mmHg and diastolic reduction of 8.2 mmHg with CoQ10 supplementation 8.

The real interaction concern: blood pressure

This is where the pharmacodynamic overlap matters. Neither BPC-157 nor CoQ10 is a strong antihypertensive on its own at commonly used doses. But if you are already taking a calcium channel blocker, ACE inhibitor, or ARB for blood pressure management, adding two compounds that each nudge pressure downward through independent mechanisms could compound the effect.

The framework below helps you categorize your personal risk level before combining these two compounds with any antihypertensive therapy:

| Your situation | Risk level | Suggested step | |---|---|---| | No antihypertensives, normal BP | Low | Monitor BP at start, 4 weeks | | On antihypertensives, BP well-controlled | Moderate | Tell your prescriber before adding either compound | | On antihypertensives, BP borderline low | Higher | Do not add without prescriber sign-off | | Pregnancy or trying to conceive | Avoid BPC-157 entirely | See pregnancy section below | | Postmenopausal on statins | Low-moderate for CoQ10; uncertain for BPC-157 | CoQ10 is reasonable; BPC-157 needs individualized discussion |

There is no published case report of symptomatic hypotension specifically from the BPC-157-plus-CoQ10 combination. The concern is theoretical but mechanistically plausible, which is why it deserves direct discussion with your prescribing clinician rather than silent self-management.

Sex-specific physiology: why this matters differently for women

Hormonal influence on CoQ10 levels

Estrogen appears to regulate mitochondrial biogenesis through estrogen-receptor-beta (ERbeta), which is expressed in mitochondria across multiple tissues 9. As estrogen declines in perimenopause, mitochondrial efficiency may drop alongside CoQ10 utilization. This is not a confirmed mechanism for the clinical deficiency you feel as fatigue, but it is a plausible biological reason why perimenopausal women report more benefit from CoQ10 supplementation than their male counterparts in some clinical settings.

CoQ10 and PCOS

Women with polycystic ovary syndrome (PCOS) often carry a heavier mitochondrial oxidative stress burden than age-matched controls. A 2022 randomized trial found that CoQ10 supplementation at 200 mg daily for 8 weeks significantly improved insulin sensitivity markers and reduced testosterone levels in women with PCOS compared with placebo. If you have PCOS and are considering CoQ10, the evidence base is more solid than it is for BPC-157.

CoQ10 and egg quality in the trying-to-conceive window

CoQ10 has a well-characterized role in oocyte energy metabolism. Mitochondrial activity in the oocyte is higher than in almost any other cell type, and CoQ10 supports the ATP production required for spindle formation during meiosis 10. A 2018 randomized trial (the OVIGYN study) found that CoQ10 600 mg daily for 60 days improved ovarian response markers in poor-prognosis IVF patients 11. BPC-157 has no published fertility data in women.

Perimenopause and postmenopause

Women in perimenopause using BPC-157 are almost always doing so through a compounded prescription framed around joint recovery, gut symptoms, or fatigue, all of which spike in the hormonal transition years. CoQ10 at this stage may support mitochondrial function, cardiovascular health, and even migraine frequency (migraine peaks in perimenopause for many women). Combining the two is common in this group, and the absence of a direct pharmacokinetic conflict means the risk is largely about blood pressure management and about the broader regulatory and safety unknowns around BPC-157 itself.

Does CoQ10 change BPC-157 pharmacokinetics?

Based on available pharmacology, the answer is no. CoQ10 is not a meaningful inhibitor or inducer of CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 12. BPC-157, as a peptide, is expected to be hydrolyzed in the gastrointestinal tract or plasma rather than metabolized by hepatic CYP enzymes, which is part of why its oral bioavailability is a matter of ongoing scientific debate. Neither compound appears on the Natural Medicines database interaction list for the other as of 2025.

No dose-separation window is required on pharmacokinetic grounds. Some practitioners recommend taking fat-soluble supplements like CoQ10 with the largest meal of the day to improve absorption, while injectable BPC-157 is typically administered subcutaneously in the morning. Those timing conventions reflect absorption optimization, not an interaction concern.

Pregnancy and lactation safety: what you need to know

BPC-157 is contraindicated in pregnancy. This is not a gray area driven by missing data alone. No human pregnancy safety data exists. Animal reproductive toxicology studies are not available in peer-reviewed literature 3. The FDA's designation of BPC-157 as a substance with significant safety concerns in compounding, combined with the complete absence of reproductive toxicity data, means that no clinician following evidence-based practice should prescribe it to a pregnant woman or a woman actively trying to conceive.

If you are using BPC-157 and plan a pregnancy, stop the compound before attempting conception. Given the lack of human half-life data, a washout period of at least 30 days is a reasonable precaution, though this is consensus opinion rather than trial-derived data.

Lactation: BPC-157 transfer into human breast milk has not been studied. As a peptide it may be hydrolyzed in the infant's gut even if transfer occurs, but "may be" is not a safety guarantee. Avoid during breastfeeding.

CoQ10 in pregnancy: CoQ10 has been studied more formally. A randomized trial examined CoQ10 200 mg daily from 20 weeks gestation for pre-eclampsia prevention and found a statistically significant reduction in pre-eclampsia risk (14.4% vs 25.6%) 13. Despite this, CoQ10 is not currently recommended by ACOG as a routine pregnancy supplement, and self-prescribing in pregnancy should always involve your OB-GYN or midwife 14. CoQ10 transfer into breast milk does occur; infant exposure is considered low and no adverse events have been reported, but formal lactation safety studies are limited.

Contraception note: Women of reproductive age using BPC-157 should use reliable contraception. This is not because BPC-157 is a confirmed teratogen, but because no reproductive safety data exists and the risk-benefit calculation clearly favors avoiding fetal exposure.

Who this is right for, and who should think twice

Women for whom CoQ10 alone makes more sense

• Women in perimenopause or postmenopause seeking mitochondrial, cardiovascular, or migraine support
• Women with PCOS looking for evidence-based adjunct support for insulin sensitivity
• Women on statins with myopathy symptoms
• Women in the TTC window who want oocyte-quality support

For all of these groups, CoQ10 has at least some trial-level evidence. BPC-157 adds unknown risk without adding proven benefit in any women's-health indication.

Women for whom the combination might be considered

• Women working with a compounding-literate physician who has documented a specific tissue-repair indication for BPC-157 (e.g., tendon injury, gut-barrier compromise) and who are not pregnant, not trying to conceive, and not breastfeeding
• Women not on antihypertensive therapy or whose prescribing physician has reviewed the blood-pressure consideration
• Women who understand the regulatory status of BPC-157 and have consented to the uncertainty

Women who should not take BPC-157 at all, regardless of CoQ10

• Any woman who is pregnant, actively trying to conceive, or breastfeeding
• Women with a history of cancer or who are at elevated cancer risk (BPC-157's pro-angiogenic mechanism is a theoretical concern in this group, though no human oncology data exists)
• Women taking anticoagulants (limited data, but NO-pathway modulation could theoretically affect platelet function)

Evidence gaps: what we genuinely do not know

W6 honesty applies here. The evidence situation for BPC-157 in women is genuinely poor. Almost all mechanistic data comes from rodent studies. No published Phase I pharmacokinetic trial in humans has been completed and peer-reviewed as of mid-2025. The ACOG, The Menopause Society, and ASRM have not issued any guidance on BPC-157 because the evidence does not yet support guideline-level statements 14.

CoQ10's evidence base is far stronger, though still not without gaps. Most large trials have enrolled mixed-sex populations, and sex-stratified analyses are rarely the primary endpoint. The 2022 PCOS trial 10 and the OVIGYN fertility data 11 are among the few women-specific datasets, and both are single-center trials with sample sizes under 200.

When you read claims online that BPC-157 "heals leaky gut" or "regenerates tendons," understand that those claims come from rodent injection studies, not from human clinical trials. That does not mean the compound is useless. It means the current evidence does not support the certainty with which those claims are often made.

Practical guidance if you are already taking both

1. Check your blood pressure now, before reading further. If you do not own a cuff, your pharmacy will measure it for free in most US states.
2. List every medication and supplement you take and share it with the clinician who prescribed your BPC-157. "Prescribed" is the key word: if you sourced BPC-157 without a prescription, that conversation needs to happen even more urgently.
3. If your systolic blood pressure is already below 110 mmHg or you have symptoms of low pressure (lightheadedness on standing, fatigue, brain fog), discuss stopping BPC-157 until you have a pressure review.
4. Take CoQ10 with your largest meal. Bioavailability increases by up to 50% when taken with fat-containing food 7.
5. Recheck blood pressure at 4 weeks.
6. If you are perimenopausal and your clinician has not discussed statin-related CoQ10 depletion with you, bring it up at your next visit. A fasting lipid panel at the time of perimenopause onset is appropriate for most women, per the American Heart Association 15.

Women with PCOS who are taking metformin should be aware that metformin, like statins, has been associated with reduced CoQ10 levels in some studies 16, making CoQ10 repletion a reasonable clinical consideration in that group.